ABBN.SW: $86.10 ▼ -2.46 (-2.78%)ASML.AS: $1,560.80 ▼ -95.00 (-5.74%)ENR.DE: $162.50 ▲ 0.00 (0.00%)GLEN.L: $537.30 ▲ 2.00 (0.37%)IFX.DE: $80.56 ▲ 0.00 (0.00%)NOKIA.HE: $12.11 ▲ 0.11 (0.92%)RIO.L: $7,280.00 ▲ 16.00 (0.22%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

Talis Biomedical Corporation

TLIS - NASDAQ

Identifiants & Marche

Ticker TLIS
ISIN US87424L2079
CIK 0001584751
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Medical - Devices

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.